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Professional antigen-presenting cells (APCs), such as dendritic cells (DCs), are central to the 
initiation and regulation of anti-cancer immunity. However, in the immunosuppressive envi-
ronment within a tumor APCs may antagonize anti-tumor immunity by inducing regulatory 
T cells (Tregs) or anergy of effector T cells due to lack of efficient costimulation. Hence, in an 
optimal setting, anti-cancer drugs have the power to reduce tumor size and thereby may 
induce the release of tumor antigens and, at the same time, modulate APC function toward 
efficient priming of antigen-specific effector T cells. Selected cytotoxic agents may revert 
APC dysfunction either by directly maturing DCs or through induction of immunogenic 
tumor cell death. Furthermore, specific cytotoxic agents may support adaptive immunity 
by selectively depleting regulatory subsets, such as Tregs or myeloid-derived suppressor 
cells. Perspectively, this will allow developing effective combination strategies with novel 
immunotherapies to exert complementary pressure on tumors via direct toxicity as well as 
immune activation. We, here, review our current knowledge on the capacity of anti-cancer 
drugs to modulate APC functions to promote durable anti-cancer immune responses.
Keywords: chemotherapy, dendritic cells, anti-tumor immunity, antigen-presenting cell, tumor-induced T cell 
dysfunction, immunogenic cell death
DCs are Central to the initiation and Regulation of Anti-Cancer 
immunity
Both the induction of endogenous anti-tumor immune responses and the successful implementation 
of immunotherapy protocols rely on adequate activation of adaptive immunity by antigen-presenting 
cells (APCs). Although innate and adaptive immune cells act in concert to fight cancer cells, T cells 
play a superior role in inducing and maintaining sustained anti-tumor immune responses (1–4). 
Professional APCs include B-cells, macrophages, dendritic cells (DCs), and skin-resident Langerhans 
cells. Among these, DCs are by far the most potent activators of adaptive immunity owing to their 
unique capacity to induce primary T cell responses (5, 6).
To initiate T cell responses in the tumor setting, DCs must first recognize tumor cells as “abnormal” 
cells. Tumor cells differ from normal cells due to expression of altered-self or neo-antigens that arise 
as a consequence of genetic instability and high mutation rates in transformed cells (7, 8). Efficient 
activation of naïve and central memory T cells requires at least three signals delivered by APCs (9, 10). 
Along with the uptake of tumor-associated antigens and presentation in the context of MHC molecules, 
professional APCs are further required to provide lymphocyte costimulation, such as through expres-
sion of the B7 molecules (CD80 and CD86) or CD40. Expression of T cell-directing cytokines and 
additional costimulatory surface receptors by DCs subsequently provides the impulse for appropriate 
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CD4+ T helper cell polarization (11). Importantly, DC maturation 
is regulated by the type, duration, and timing of danger/stress 
signals, such as pathogen-associated molecular patterns (PAMPs) 
or damage-associated molecular patterns (DAMPs), both of 
which trigger DC-intrinsic pattern-recognition receptors (12–14). 
Consequently, these signals determine the quality and quantity of 
costimulation provided by DCs and thus have the power to define 
the outcome of T cell immunity.
Tumor cells may undergo cell death due to hypoxia and nutrient 
deprivation (15) resulting in the release of host-derived DAMPs 
as an indicator of a dying or “stressed” cell. Thus, on theoretical 
grounds, tumors may provide the basic elements needed for the 
initiation of successful anti-tumor immune responses. However, it 
is well established that the immune-suppressive microenvironment 
of progressive tumors may severely interfere with both APC and 
T cell activation, thereby limiting the induction of endogenous anti-
tumor immunity and the success of immunotherapies. Importantly, 
numerous tumor-mediated mechanisms may induce DC dysfunc-
tion, leading to immature or semi-mature DCs that are incapable of 
providing the necessary activation signals (16, 17). Consequently, 
under these circumstances, antigen presentation will typically pro-
voke T cell tolerance including T cell anergy, peripheral T cell clonal 
deletion, or the induction of regulatory T cells (Tregs) (18–21).
In light of the recent success of novel immunotherapy 
approaches, future therapeutic efforts will ultimately focus on 
the development of effective combination strategies that exert 
complementary pressure on tumors via immune activation and 
additional direct toxicity. Of note, accumulating evidence reveals 
unrecognized immune-modulatory features of chemo- and radio-
therapy (22, 23). In addition to reducing the primary tumor bur-
den and thereby, at least in part, reverting the immunosuppressive 
microenvironment, specific compound classes can also induce 
DC maturation, enhance antigen cross-presentation, selectively 
eliminate immunosuppressive cells, or induce immunogenic cell 
death (ICD) (24, 25). These mechanisms may provide the basis 
for initiation of anti-tumor immunity and therefore support the 
successful implementation of T cell-mediated immunotherapy 
protocols, such as blockade of inhibitory receptors. Consequently, 
chemo-immunotherapy protocols are being evaluated in numer-
ous clinical studies with promising therapeutic activity (26).
A major drawback of cytotoxic anti-cancer agents is their 
possible interference with T cell activation and clonal expansion 
(27, 28). A precise definition of the immune-modulating proper-
ties of cytotoxic therapies is, therefore, crucial for optimizing 
chemo-immunotherapy regimens. Here, we review the current 
knowledge on the capacity of anti-cancer drugs to modulate the 
phenotype and function of APCs, and in particular, the impact of 
these agents on T cell effector functions.
Modulation of APC Function by  
Anti-Cancer Chemotherapeutics
Direct DC Maturation by Cytotoxic Anti-Cancer 
Agents
A lack of T cell effector function is mostly caused by inefficient 
expression of costimulatory molecules on tumor-associated DCs 
or by dysregulation of DC maturation pathways (29). Therefore, 
understanding how cytotoxic agents influence DC maturation is 
vital for designing effective chemo-immunotherapy protocols. 
An improved DC phenotype associated with T cell activation 
in  vitro was reported after treatment of immature DCs with 
the topoisomerase I inhibitor topotecan. In contrast, treatment 
of lipopolysaccharide-matured DCs with topotecan resulted in 
decreased allogeneic T cell responses accompanied with a shift 
toward TH2 responses and increased IL-10 in co-cultures (30). 
Therefore, topoisomerase inhibitors might down-modulate 
responses of previously activated tumor-resident DCs, suggest-
ing limited suitability for T cell immunotherapy combinations. 
Studies on other topoisomerase I inhibitors report conflicting 
results on DC maturation (31, 32). Also, using a DC-based reporter 
system, nine of 12 investigated compounds were identified as DC 
stimulatory (33). The effects of topoisomerase inhibitors on the 
induction of anti-tumor immunity as well as T cell activation and 
expansion in vivo, therefore, require further investigations.
Liu and colleagues revealed mechanistic insights into the 
molecular events associated with chemotherapy-induced DC 
maturation (32). Expression of the cell cycle regulator p21waf1/cip1 
in human DCs was associated with a favorable DC phenotype 
and was shown to be upregulated by cytotoxic agents. p21waf1/cip1 
expression correlated with enhanced expression of CD83 and 
CD86 in response to the anti-malaria agent artesunate and several 
anti-cancer compounds including camptothecin, lenalidomide, 
and docetaxel (32). When considering the “two-signal model” in 
innate immune activation (34), it seems plausible that p21, which 
generally indicates intrinsic cell stress, is activated in response 
to cytotoxicity. This “cell stress” or “abnormal condition” in the 
innate cell itself may deliver the necessary secondary signal for 
complete activation of innate immune cells and therefore result 
in enhanced DC maturation.
Along the same line, microtubule-destabilizing agents 
(MDAs), such as the Vinca-alkaloids, dolastatins, or maytansines, 
can directly affect DC maturation. Early studies indicated that 
microtubule disruption by colchicine, vinblastine, and vin-
cristine induced marked expression of IL-1 in monocytes (35). 
Interestingly, rupture of the actin filaments by cytochalasins 
could not recapitulate this effect. Broad immune-stimulatory 
effects on murine DCs upon colchicine or vinblastine treatment, 
including expression of further pro-inflammatory cytokines and 
enhanced cross-presentation, have subsequently been confirmed 
by Takashima and colleagues (33, 36, 37). In extension of those 
data, we were able to demonstrate that two further families of 
MDAs, the dolastatins and maytansines, potently induced DC 
maturation. Importantly, DC pre-treatment with these agents 
induced profound T cell immunity, while treatment of tumor-
bearing mice synergized with blockade of CTLA-4 and PD-1. 
Mechanistically, tumor rejection could be explained by enhanced 
infiltration of lymphocytes into the tumors and a shift toward an 
increased effector T cell to Treg ratio (38–40). Experiments to 
elucidate DC signaling pathways induced by MDAs are currently 
ongoing.
In stark contrast, we did not detect significant changes in DC 
 phenotype or cytokine expression upon exposure to microtubule- 
stabilizing agents (MSA), such as the taxane-family of compounds (38). 
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Various studies have reported modulation of DC phenotype upon 
exposure to low, non-cytotoxic, concentrations of paclitaxel and other 
chemotherapeutics (41–44). However, these studies mostly evaluated 
DC function and phenotypic maturation in the context of paclitaxel 
pre-treated tumor cells or in combination with lipopolysaccharide 
treatment. Direct effects of paclitaxel and other MSAs on DCs were 
generally very moderate and thus are largely consistent with our 
data. The stimulatory effects of paclitaxel on tumor-associated mac-
rophages, which subsequently may lead to activation of intra-tumoral 
immune cells, such as DCs, NK cells, and cytotoxic T lymphocytes, 
are comprehensively reviewed elsewhere (45).
Antibody-drug conjugates (ADCs) are emerging as powerful 
treatment strategies with outstanding target specificity and high 
therapeutic activity in cancer patients. The immune-modulatory 
capacities of dolastatins and maytansines are of particular clinical 
interest as their synthetic analogs, i.e., monomethyl auristatin E 
(MMAE) and DM1, are used as cytotoxic payloads of ADCs (46). 
Importantly, in tumor-bearing mice, DC activation upon treatment 
with such ADCs is equally potent as observed after administration 
of the respective free compound. Upon internalization, the cytotoxic 
payload is released into the tumor cell cytoplasm but may also diffuse 
into the surrounding microenvironment (47). Notably, the latter may 
induce maturation of tumor-resident DCs. We detected increased 
CD8 and CD4 T cell infiltrates, activation of APCs and T cells as 
well as reduced Treg frequencies in patients treated with the MMAE-
carrying ADC Brentuximab Vedotin (BV) (39). Furthermore, 
induction of long-lasting tumor-specific T cells was detected in 
relapsed lymphoma patients responding to BV (with or without 
donor lymphocyte infusions) post-allogeneic HSCT (48, 49).
DC Stimulation via immunogenic Cell Death
Apoptotic cell death was historically considered to be non-
immunogenic. However, some types of cell death have been 
demonstrated to induce an immune response against antigens 
released from dying cells, commonly referred to as immunogenic 
cell death (ICD). Immunogenic signals released by dying tumor 
cells can induce antigen uptake as well as antigen processing and 
presentation by the APC. Although cytotoxic anti-cancer therapies 
generally induce apoptosis, ICD is only induced in treatment with 
some of these agents, particularly, anthracyclines (50), oxaliplatin 
(51), and cyclophosphamide (52) as well as for irradiation (50). ICD 
is characterized by the induction of endoplasmic reticulum (ER) 
stress and autophagy, which is in distinction to non-immunogenic 
apoptosis (53, 54). Hallmarks of ICD include the pre-apoptotic 
exposure of calreticulin (CRT) on the cell surface, the secretion 
of adenosine triphophosphate (ATP), and the post-apoptotic 
release of the chromatin-binding protein high-mobility group box 
1 (HMGB1) (50, 55, 56). Importantly, the suppression of each of 
these signals abolishes the immunogenicity of cell death, demon-
strating the non-redundancy of each of these pathways (50, 55, 56).
Cytotoxic agents that trigger ICD are also efficient inducers of 
CRT cell-surface exposure. CRT is under normal circumstances 
located at the membrane of the ER. Following the induction of an 
ER stress response, CRT translocates to the cell surface where it 
serves as an established “eat me signal” for apoptotic cells (50, 54). 
This occurs well before the induction of apoptotic changes, such 
as the surface exposure of phosphatidylserine. Binding of CRT to 
CD91 on phagocytes induces phagocytosis and macropinocytosis 
leading to the efficient clearance of these cells (57). CRT is also 
detectable on the surface of viable cells; however, the expression 
of the surface molecule CD47 and its binding to SIRP-α on 
phagocytes efficiently inhibits the uptake of viable cells (57). The 
induction of CRT surface expression on tumor cells by cytotoxic 
agents efficiently mediates their uptake by DCs (50). Importantly, 
CRT-CD91 interaction leads to signaling through NF-κB in 
DCs and to the release of inflammatory cytokines, in particular 
TNF, IL-6, IL-1β, and IL-12. This cytokine milieu induced by 
CRT exposure leads to Th17 priming in an immunosuppressive, 
TGF-β containing, microenvironment (58).
Adenosine triphophosphate release by dying tumor cells mani-
fests the second hallmark of ICD and is one of the most prominent 
“find-me” signals for myeloid cells. Upon treatment with selected 
cytotoxic agents, tumor cells secrete ATP in an autophagy-
dependent fashion (53, 59). ATP induces recruitment of myeloid 
cells into the tumor upon its binding to P2Y2 receptors (55). In 
the second step, ATP facilitates myeloid cells to differentiate into 
inflammatory DCs. Furthermore, ATP activates P2RX7 receptors 
on DCs, which activates the NLRP3 inflammasome leading to 
IL-1β release. Of note, IL-1β then is required for the priming of 
CD8+ T cells (60). Importantly, priming of T cells appears to occur 
predominantly in the tumor microenvironment as no significant 
abrogation in T cell priming is maintained in a mouse model 
upon surgical removal of draining lymph nodes (55).
High-mobility group box 1 is a chromatin-binding factor 
found within the nucleus that can be released by injured cells 
as they undergo primary or secondary necrosis and thereby 
induces inflammation (61). Treatment of tumor cells by ICD-
inducing cytotoxic compounds leads to a post-apoptotic release 
of HMGB1, which is recognized by TLR4 on DCs. TLR4 controls 
the tumor antigen processing and is, therefore, indispensable 
for efficient cross-presentation of tumor cell antigens by DCs 
(56). In the absence of TLR4 stimulation, phagosomes fuse with 
lysosomes, which results in degradation of dying cells in the 
lysosomal compartment, and consequently inefficient antigen 
presentation (56, 62). In esophageal squamous cell carcinoma, 
levels of HMGB1 within the tumor microenvironment were 
significantly upregulated upon preoperative chemoradiotherapy 
and patients with a high HMGB1 levels showed a better overall 
survival compared to those with weak HMGB1 expression 
(63). These findings underline the clinical relevance of HMGB1 
expression. However, the inter-patient variability of HMGB1 
expression remains poorly understood. HMGB1 can also bind the 
T cell immunoglobulin- and mucin-domain containing molecule 
(Tim-3) that is preferentially expressed on tumor-infiltrating DCs 
(64). Galectin-9 independent ligation of Tim-3 with HMGB1 
leads to a negative regulation of nucleic acid-mediated innate 
immune responses. It is, therefore, reasonable to hypothesize that 
the balance between a positive signal through TLR4 ligation and 
a negative signal through Tim-3 ligation might regulate the ICD 
induced activation of tumor-resident DCs.
While the described mechanisms leading to ICD are able to 
induce efficient antigen presentation and cytokine secretion, 
costimulatory molecules might not be upregulated in most of 
these ICD-inducing chemotherapeutic regiments (50, 55, 56), 
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Cytotoxic Agents Targeting Tumor-Resident 
immunosuppressive Cells
Regulatory T cells interfere with anti-tumor immune responses 
by several mechanisms [reviewed in Ref. (65)]. For example, 
Tregs may inhibit DC maturation via CTLA-4/CD80/CD86 inter-
action and induce expression of the immunosuppressive enzyme 
indoleamine-2,3-dioxygenase (IDO) (66, 67). Several cytotoxic 
agents are able to target Tregs and thereby promote adaptive anti-
tumor immunity. One of the first drugs reported to interfere with 
Tregs was cyclophosphamide. At low doses, cyclophosphamide 
depletes Tregs and inhibits their effector functions and homeo-
static proliferation, as demonstrated in mouse models and patients 
(68–71). Consequently, low-dose cyclophosphamide treatment 
promotes tumor-specific immune responses when combined with 
different vaccination strategies, including DC-derived exosomes 
(DEX) (72) and oncolytic adenovirus (73). Yet, the mechanisms 
underlying this synergy need to be further elucidated. However, 
it is reasonable, that in the absence of Tregs, CD4+ T cells might 
activate tumor-resident DCs through CD40L–CD40 interaction, 
which then can efficiently present tumor antigen and promote 
T cell activation (74, 75). Additional chemotherapeutic agents 
targeting Tregs include paclitaxel, which selectively induces 
apoptosis of Tregs by upregulation of the cell death receptor Fas 
(76), and low-dose temozolomide, which reduces Treg numbers 
through poorly understood molecular mechanisms (77, 78).
Myeloid-derived suppressor cells (MDSCs) are a heterogene-
ous population of immature myeloid cells located in the tumor 
microenvironment and lymphatic organs. These cells can inhibit 
innate and adaptive immune responses [reviewed in Ref. (79)]. 
Several chemotherapeutic drugs can promote anti-tumor immu-
nity by either inducing apoptosis of MDSCs or inducing their 
differentiation into mature myeloid cells with features of DCs or 
macrophages. 5-Fluorouracil (5-FU) and gemcitabine substan-
tially reduce the numbers of MDSCs by induction of apoptosis 
(80, 81). In addition, both 5-FU and gemcitabine induce activa-
tion of NLRP3 in dying MDSCs following release of cathepsin B 
from lysosomes. Active NLRP3 triggers secretion of IL-1β, which 
may induce IL-17 production by T cells, resulting in priming of 
Th17 cells, neoangiogenesis, and promotion of tumor growth 
(82). As 5-FU and gemcitabine, however, do not induce ICD, 
the measured IL-1β concentrations appear to be low compared 
to the IL-1β secretion triggered by ICD-inducing chemothera-
peutics (80). Importantly, at low concentrations, IL-1β does not 
support the priming of CD8+ T cells and the detrimental effects 
of IL-1β prevail. Therefore, the therapeutic potential of 5-FU and 
gemcitabine treatment could be enhanced by co-administration 
of IL-1β inhibitors. Importantly, 5-FU-induced depletion of 
MDSCs acts synergistically with Treg depletion induced by low-
dose cyclophosphamide treatment, enhancing T cell functions 
and anti-tumor responses (80). A similar selective depletion of 
MDSCs and subsequent enhancement of T cell immunity was 
seen during treatment with doxorubicin or 5-azacytidine (83, 84).
In contrast, non-toxic, low doses of paclitaxel stimulate the 
differentiation of MDSCs into functional DCs expressing MHCII 
and costimulatory molecules (85, 86). These functional DCs have 
lost their suppressive capacity and contribute to the induction of 
T cell responses. Similarly, docetaxel treatment polarizes MDSCs 
toward an M1 phenotype with loss of suppressive effects, higher 
levels of MHCII and CD80 expression, and a shift from IL-10 to 
IL-12 secretion (87).
Concluding Remarks
The cytotoxic agents that have been used for several decades for 
anti-cancer therapy were originally selected for their ability to kill 
tumor cells. Some, but not all, of these reagents are now known 
to stimulate anti-tumor immunity, which contributes to their 
therapeutic effect. A detailed characterization of the immune-
stimulatory effects of currently used chemotherapeutic agents 
should guide the way for rational combinations with immu-
notherapeutic approaches, which should stimulate anti-tumor 
immune responses in a synergistic fashion. Cytotoxic agents 
that directly induce DC maturation or ICD are ideal candidates 
for combining with inhibitors of immune checkpoints such as 
PD-1 or CTLA-4, which may result in a long-lasting population 
of effector memory CD8+ T cells (38, 39). In addition, the selec-
tive depletion of immune-inhibitory subsets, such as Tregs and 
MDSCs induced by chemotherapeutic agents, may complement 
active vaccination strategies and/or checkpoint blockade, by 
strengthening effector T cell populations (72, 73). The findings 
discussed here provide the basis for the further development of 
rational immunotherapeutic protocols in the near future.
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